Follow
Andrew X Chen
Andrew X Chen
Verified email at columbia.edu
Title
Cited by
Cited by
Year
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
J Zhao, AX Chen, RD Gartrell, AM Silverman, L Aparicio, T Chu, ...
Nature medicine 25 (3), 462-469, 2019
6382019
Spatiotemporal genomic architecture informs precision oncology in glioblastoma
JK Lee, J Wang, JK Sa, E Ladewig, HO Lee, IH Lee, HJ Kang, ...
Nature genetics 49 (4), 594-599, 2017
2642017
Predicting clinical outcomes in glioblastoma: an application of topological and functional data analysis
L Crawford, A Monod, AX Chen, S Mukherjee, R Rabadán
Journal of the American Statistical Association 115 (531), 1139-1150, 2020
125*2020
Tissue-resident memory T cells mediate immune homeostasis in the human pancreas through the PD-1/PD-L1 pathway
SP Weisberg, DJ Carpenter, M Chait, P Dogra, RD Gartrell-Corrado, ...
Cell reports 29 (12), 3916-3932. e5, 2019
902019
Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state
D Cerezo-Wallis, M Contreras-Alcalde, K Troulé, X Catena, C Mucientes, ...
Nature medicine 26 (12), 1865-1877, 2020
682020
Single-cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro-tumor marker
AX Chen, RD Gartrell, J Zhao, PS Upadhyayula, W Zhao, J Yuan, ...
Genome medicine 13 (1), 88, 2021
592021
Dynamics of a producer-freeloader ecosystem on the brink of collapse
A Chen, A Sanchez, L Dai, J Gore
Nature communications 5 (1), 3713, 2014
492014
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma
VA Arrieta, AX Chen, JR Kane, SJ Kang, C Kassab, C Dmello, J Zhao, ...
Nature cancer 2 (12), 1372-1386, 2021
462021
A phase I study of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable sarcoma and malignant peripheral nerve sheath tumors
GA Manji, BA Van Tine, SM Lee, AG Raufi, I Pellicciotta, AC Hirbe, ...
Clinical Cancer Research 27 (20), 5519-5527, 2021
372021
Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
J Zhao, AX Chen, RD Gartrell, AM Silverman, L Aparicio, T Chu, ...
Nature medicine 25 (6), 1022-1022, 2019
212019
Linking transcriptomic and imaging data defines features of a favorable tumor immune microenvironment and identifies a combination biomarker for primary melanoma
RD Gartrell-Corrado, AX Chen, EM Rizk, DK Marks, MH Bogardus, ...
Cancer research 80 (5), 1078-1087, 2020
202020
Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma
RD Gartrell, T Enzler, PS Kim, BT Fullerton, L Fazlollahi, AX Chen, ...
Oncoimmunology 11 (1), 2066767, 2022
92022
A fast semi-automatic segmentation tool for processing brain tumor images
AX Chen, R Rabadán
Towards Integrative Machine Learning and Knowledge Extraction: BIRS Workshop …, 2017
52017
Scale-free structure of cancer networks and their vulnerability to hub-directed combination therapy
AX Chen, CJ Zopf, J Mettetal, WC Shyu, J Bolen, A Chakravarty, S Palani
bioRxiv, 2020.07. 01.159657, 2020
12020
Using game theory to investigate the therapeutic potential of disrupting tumor-microenvironment interactions
D Van Egeren, A Chen, M Stoddard, L Yuan, A Chakravarty
Cancer Research 84 (6_Supplement), 7378-7378, 2024
2024
Model-derived progression-free survival (mPFS): A better metric for patient-derived xenograft studies
A Chen, M Stoddard, L Yuan, D Van Egeren, A Chakravarty, D Bottino
Cancer Research 84 (6_Supplement), 6904-6904, 2024
2024
Understanding three-drug combinations: optimizing scheduling while avoiding toxicity
M Stoddard, L Yuan, D Van Egeren, A Chen, D Bottino, A Chakravarty
Cancer Research 84 (6_Supplement), 4761-4761, 2024
2024
Impact of drug combination schedules on the evolution of tumor resistance
M Stoddard, A Chen, L Yuan, D Van Egeren, D Bottino, A Chakravarty
Cancer Research 84 (6_Supplement), 4310-4310, 2024
2024
Blood brain barrier masks effects of dosing strategy
M Stoddard, A Chen, L Yuan, D Van Egeren, A Chakravarty
Cancer Research 84 (6_Supplement), 7182-7182, 2024
2024
Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma
AG Raufi, I Pellicciotta, C Palermo, S Sastra, A Chen, E Alouani, C Maurer, ...
bioRxiv, 2023.12. 24.573257, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–20